These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16428244)

  • 21. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
    Pfeiffer P; Mortensen JP; Bjerregaard B; Eckhoff L; Schønnemann K; Sandberg E; Aabo K; Jakobsen A
    Eur J Cancer; 2006 Nov; 42(16):2738-43. PubMed ID: 17011184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.
    Twelves C;
    Eur J Cancer; 2002 Feb; 38 Suppl 2():15-20. PubMed ID: 11841931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral capecitabine (Xeloda) in cancer treatment.
    Doyle DP; Engelking C
    Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
    [No Abstract]   [Full Text] [Related]  

  • 24. [Capecitabine in the treatment of colorectal cancer].
    Zeuli M; Pino MS; Cognetti F
    Tumori; 2001; 87(1 Suppl 1):S55-6. PubMed ID: 11300027
    [No Abstract]   [Full Text] [Related]  

  • 25. [Oral capecitabine therapy: experience and developments at the Milano Cancer Institute].
    Longo F; Mansueto G
    Tumori; 2004; 90(1):suppl 17-27. PubMed ID: 15143996
    [No Abstract]   [Full Text] [Related]  

  • 26. In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht.
    Cassidy J
    Ann Oncol; 2006 Sep; 17(9):1469-71. PubMed ID: 16684792
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of oral chemotherapy in colorectal cancer.
    Donehower RC
    Oncology (Williston Park); 2000 Nov; 14(11A):243-5. PubMed ID: 11195416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Cassidy J; Schmoll HJ; Van Cutsem E
    J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
    [No Abstract]   [Full Text] [Related]  

  • 29. [Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
    Hosokawa A
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():352-5. PubMed ID: 14574911
    [No Abstract]   [Full Text] [Related]  

  • 30. Capecitabine: fulfilling the promise of oral chemotherapy.
    Hwang JJ; Marshall JL
    Expert Opin Pharmacother; 2002 Jun; 3(6):733-43. PubMed ID: 12036413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of capecitabine in the treatment of colorectal cancer in the elderly.
    Pasetto LM; Monfardini S
    Anticancer Res; 2006; 26(3B):2381-6. PubMed ID: 16821620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
    Booth C
    J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
    [No Abstract]   [Full Text] [Related]  

  • 35. X-ACT: an important step on an unfinished journey.
    Maughan T
    Ann Oncol; 2012 Jul; 23(7):1655-8. PubMed ID: 22517823
    [No Abstract]   [Full Text] [Related]  

  • 36. [Adjuvant chemotherapy for colorectal carcinoma after curative resection].
    Murakami M; Tsukuda K; Ota T; Naito M; Shimizu N
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():449-53. PubMed ID: 14574933
    [No Abstract]   [Full Text] [Related]  

  • 37. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
    Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
    J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral treatment for gastric cancer: new choices, better choices?
    Cascinu S
    Lancet Oncol; 2008 Mar; 9(3):188-9. PubMed ID: 18308239
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
    Jansman FG; Postma MJ; van Hartskamp D; Willemse PH; Brouwers JR
    Clin Ther; 2004 Apr; 26(4):579-89. PubMed ID: 15189755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.